By the Numbers

The impact of higher agency loan limits on PLS issuance

| October 15, 2021

This document is intended for institutional investors and is not subject to all of the independence and disclosure standards applicable to debt research reports prepared for retail investors. This material does not constitute research.

Growth in the prime private-label MBS market should get a challenge next year from substantially higher conforming loan limits. Nearly unprecedented year-over-year home price appreciation may lift conforming and jumbo conforming limits by nearly 20% next year, giving Fannie Mae and Freddie Mac purview to purchase loans with balances close to $1 million in certain high-cost areas. The potentially new reach of the enterprises could weigh on private issuance, although that will likely hinge on how the GSEs choose to price guarantee fees for larger loans.

The growth in private-label issuance this year has been fueled in no small part by a flow of agency-eligible loans into private-label trusts. But the GSEs could be taking some of that share back next year. FHFA has already lifted the caps on the amount of non-owner-occupied loans that the GSEs can purchase and will likely use risk-based pricing on those loans rather than hard limits on purchases to govern GSE originations going forward. A big bump in the original balance of loans that the GSEs can purchase may further encroach on private-label issuance next year.

As of June, FHFA’s Home Price Index was up roughly 12% over the prior June reading. A more recent CoreLogic reading has home values up 18.1% year-over-year through August. Assuming FHFA’s measurement is roughly in-line with Core Logic estimates, conforming and jumbo conforming loan balances could rise close to 20% next year. An 19% increase in balances would push the conforming limit next year to nearly $650,000 and the limit for high-cost areas, which is 150% of the conforming balance, to nearly $1 million.

Exhibit 1: Home price appreciation may push limits on GSE eligible loans to nearly $1 million

Source: FHFA, Bloomberg LP

There is a very small possibility that FHFA may not raise loan limits to the full extent allowed. The impetus for a smaller increase would be primarily due to safety and soundness concerns, which historically has been an area of focus for acting Director Thompson. However, the higher probability event appears to be that FHFA will increase loan limits in accordance with the rise in home values.

Sizing the impact of loan size changes

The headline impact of increasing loan limits on the $30 billion of prime loans securitized in private trusts this year would be massive. Over two-thirds of loans securitized in PLS trusts this year had balances less than $1 million. However, the real impact is likely far more subtle as this does not consider whether the loans would qualify for the high-cost limit. Sponsors of securitizations do not uniformly disclose whether loans are agency-eligible, and ZIP code data is often not available at the loan level. Classifying a loan as conforming or conforming jumbo relies on some higher-level assumptions.  Based solely on original loan balance, the number of units and state-level geography, some assumptions can be made as to whether a loan would qualify for a conforming jumbo balance. However, this methodology will likely overstate the amount of loans that would qualify for the higher limit as the home may not be a high-cost area of a given state.

A 19% increase in both conforming and conforming jumbo limits would unsurprisingly shift the mix of conforming, jumbo conforming and non-conforming loans securitized in private trusts this year somewhat materially. Based on existing limits, over two-thirds of loans securitized in private trusts were non-conforming. A 19% increase in GSE loan limits would reduce that number to just below 50% (Exhibit 2).

Exhibit 2: Higher loan limits shift the mix of agency-eligible loans in PLS trusts

Note: Data show prime jumbo private-label securitizations YTD for 2021. The “2021 Limit” shows the current mix. The “2022 Estimated Limit” shows the mix that would prevail if projected higher agency loan limits applied to 2021 YTD production.
Source: CoreLogic, Intex, Amherst Pierpont

FHFA and the administration by proxy will likely face a balancing act between the negative optics that come with providing financing for million-dollar single-family homes and the valuable guarantee fee income associated with those loans, which could be used to cross-subsidize affordable housing. One potential solution would be to increase guarantee fees on higher cost homes either in the form of a broad-based incremental delivery charge or a loan level pricing adjustment. The question of whether to raise charges on higher balance loans does not appear to be a front-burner issue but could come into focus early next year. And increasing fees on higher balance loans would itself be somewhat of a balancing act. A material uptick in the cost of financing for more creditworthy borrowers would likely push more of those loans to private-label channels especially among larger originators with existing ability to tap the private-label market.

Most jumbo conforming loans still get better private-label execution

While the population of loans eligible for GSE delivery looks poised to grow, better private-label execution may stem the flow of higher balance loans to the GSEs to some extent. Assuming a 2.5% pass through execution at $1-16/32s behind the UMBS benchmark, nearly 80% of conforming jumbo loans delivered to the GSEs in August of this year would have fetched at least a quarter-point higher price through private-label execution. If private-label pass through spreads were to widen by an additional half point it would only change best execution economics for 8% of those loans as nearly 70% of August’s conforming jumbo production would have still achieved a higher price, had they been delivered into private-label execution (Exhibit 3).

Exhibit 3: Conforming jumbo loans may still get better private-label execution

Source: eMBS, Fannie Mae, Freddie Mac, Amherst Pierpont

Recently spreads across lower coupon conforming jumbo specified pools have tightened dramatically against TBA benchmarks, driven by a lack of supply as originators are likely holding back production to deliver into higher limits for forward delivery next year. And as a result, GSE execution may be moderately better than the analysis may suggest. However, as the supply technical abates, spreads on conforming jumbo pools should widen back out, and if they do, many conforming jumbo loans may still achieve better prices by being sold to private-label conduits.

GSE pricing will also weigh heavily on the impact of higher limits on private-label supply. One of the big drivers of private-label execution this year was the 50 bp Adverse Market Delivery Charge that the GSEs applied to all refinances. That blanket charge expired earlier this year. However, the removal of that charge did little to impact best execution on conforming jumbo loans as the above analysis shows. Additionally, and potentially more significantly, the jumbo conforming loans analyzed already carry an average of one point of LLPAs. If FHFA were to apply a broad-based LLPA increase to all conforming jumbo loans that would further improve private-label execution on a cohort of loans where most of them are already better executed in the private-label market. As a result, higher LLPAs on these loans would likely be the biggest reason why private-label volumes may remain elevated next year despite higher GSE loan limits.

Chris Helwig
chelwig@apsec.com
chelwig

This material is intended only for institutional investors and does not carry all of the independence and disclosure standards of retail debt research reports. In the preparation of this material, the author may have consulted or otherwise discussed the matters referenced herein with one or more of SCM’s trading desks, any of which may have accumulated or otherwise taken a position, long or short, in any of the financial instruments discussed in or related to this material. Further, SCM may act as a market maker or principal dealer and may have proprietary interests that differ or conflict with the recipient hereof, in connection with any financial instrument discussed in or related to this material.

This message, including any attachments or links contained herein, is subject to important disclaimers, conditions, and disclosures regarding Electronic Communications, which you can find at https://portfolio-strategy.apsec.com/sancap-disclaimers-and-disclosures.

Important Disclaimers

Copyright © 2024 Santander US Capital Markets LLC and its affiliates (“SCM”). All rights reserved. SCM is a member of FINRA and SIPC. This material is intended for limited distribution to institutions only and is not publicly available. Any unauthorized use or disclosure is prohibited.

In making this material available, SCM (i) is not providing any advice to the recipient, including, without limitation, any advice as to investment, legal, accounting, tax and financial matters, (ii) is not acting as an advisor or fiduciary in respect of the recipient, (iii) is not making any predictions or projections and (iv) intends that any recipient to which SCM has provided this material is an “institutional investor” (as defined under applicable law and regulation, including FINRA Rule 4512 and that this material will not be disseminated, in whole or part, to any third party by the recipient.

The author of this material is an economist, desk strategist or trader. In the preparation of this material, the author may have consulted or otherwise discussed the matters referenced herein with one or more of SCM’s trading desks, any of which may have accumulated or otherwise taken a position, long or short, in any of the financial instruments discussed in or related to this material. Further, SCM or any of its affiliates may act as a market maker or principal dealer and may have proprietary interests that differ or conflict with the recipient hereof, in connection with any financial instrument discussed in or related to this material.

This material (i) has been prepared for information purposes only and does not constitute a solicitation or an offer to buy or sell any securities, related investments or other financial instruments, (ii) is neither research, a “research report” as commonly understood under the securities laws and regulations promulgated thereunder nor the product of a research department, (iii) or parts thereof may have been obtained from various sources, the reliability of which has not been verified and cannot be guaranteed by SCM, (iv) should not be reproduced or disclosed to any other person, without SCM’s prior consent and (v) is not intended for distribution in any jurisdiction in which its distribution would be prohibited.

In connection with this material, SCM (i) makes no representation or warranties as to the appropriateness or reliance for use in any transaction or as to the permissibility or legality of any financial instrument in any jurisdiction, (ii) believes the information in this material to be reliable, has not independently verified such information and makes no representation, express or implied, with regard to the accuracy or completeness of such information, (iii) accepts no responsibility or liability as to any reliance placed, or investment decision made, on the basis of such information by the recipient and (iv) does not undertake, and disclaims any duty to undertake, to update or to revise the information contained in this material.

Unless otherwise stated, the views, opinions, forecasts, valuations, or estimates contained in this material are those solely of the author, as of the date of publication of this material, and are subject to change without notice. The recipient of this material should make an independent evaluation of this information and make such other investigations as the recipient considers necessary (including obtaining independent financial advice), before transacting in any financial market or instrument discussed in or related to this material.

The Library

Search Articles